A new phase of European health policy began on 12 January 2025, when Regulation (EU) 2021/2282 on Health Technology Assessment became applicable. Its significance goes beyond another layer of EU healthcare legislation. The Regulation changes the way Member States cooperate when determining the clinical value of new medicines and selected medical technologies.

Health technology assessment sits at a critical point between innovation and patient access. Regulatory approval establishes whether a medicine or device can be placed on the market. HTA, by contrast, helps public authorities determine how a technology compares with available alternatives and how it should be considered within a healthcare system.

Historically, much of this assessment work has been organised nationally. The result has been a fragmented European environment: developers may face different evidence expectations in different countries, while national authorities can end up examining similar clinical information several times.

What the EU is changing

The new framework establishes structured cooperation among national and regional HTA authorities. Its most visible instrument is the Joint Clinical Assessment, or JCA.

A JCA examines the relative clinical effectiveness and relative safety of a health technology against relevant alternatives. Rather than each Member State independently repeating the core clinical assessment, experts from across the Union cooperate on a common scientific report.

National authorities can therefore use the European clinical assessment within their own procedures while retaining responsibility for economic analysis, budget impact, reimbursement conditions and other national considerations.

A phased implementation rather than a single switch

The Regulation deliberately introduces the new system in stages. This gives authorities, developers and healthcare systems time to adjust to a common methodology and build the administrative capacity needed for EU-level cooperation.

• 2025 New cancer medicines containing new active substances and advanced therapy medicinal products enter the Joint Clinical Assessment framework.
• 2026 Selected high-risk medical devices and certain in-vitro diagnostic devices begin to enter the EU assessment process.
• 2028 Orphan medicinal products are brought within the mandatory Joint Clinical Assessment system.
• 2030 The framework extends to all other new medicinal products covered by the Regulation.

Why the reform matters for patients

For patients, the potential benefit lies principally in reducing unnecessary delays between innovation and effective access. A medicine can receive marketing authorisation while still taking considerable time to move through national assessment and reimbursement processes.

The new system cannot eliminate every national difference. Healthcare budgets, treatment pathways and reimbursement rules remain different across Europe. But a common clinical evidence base can reduce duplicated work and make the assessment process more predictable.

It may also improve consistency. When Member States begin from the same joint scientific assessment, differences in subsequent national decisions should become easier to identify and explain.

Patients and clinicians gain a formal role

The Regulation also gives greater importance to the experience of patients, carers and clinical experts. They can contribute to Joint Clinical Assessments and Joint Scientific Consultations, helping ensure that the questions being examined reflect clinical practice and the outcomes that matter to patients.

This matters because statistical evidence alone does not always reveal the complete value of a treatment. Effects on daily functioning, quality of life, burden on carers or the practical usability of a therapy can be highly relevant when comparing alternative treatments.

What changes for pharmaceutical and technology developers

For industry, the new system offers the prospect of greater predictability but also requires earlier and more coordinated evidence planning.

Developers of technologies falling within the scope of Joint Clinical Assessment must prepare for an EU-level process running alongside the regulatory pathway. Clinical evidence therefore needs to be capable of answering questions relevant not only to marketing authorisation but also to comparative assessment.

This makes the relationship between clinical development, regulatory strategy and market-access strategy increasingly important. A trial programme capable of demonstrating safety and efficacy may not automatically provide every comparison needed by HTA authorities.

Joint Scientific Consultations: preparing before the evidence exists

The framework also provides for Joint Scientific Consultations. These allow developers to seek advice on the evidence likely to be required for a future assessment before clinical development is complete.

In principle, this can reduce the risk of discovering too late that studies have not generated the comparisons or outcomes required by European HTA authorities. For innovative companies, especially those developing complex or highly specialised therapies, that earlier dialogue may become an important part of market-access planning.

Member States keep control — but work from a common foundation

The new EU system should not be confused with the creation of a European healthcare payer. National governments retain control over healthcare organisation and over decisions concerning price and reimbursement.

The major change is instead procedural and scientific. Member States are required to take the joint clinical work into account in their national HTA processes rather than recreating the same assessment independently.

This balance between common European evidence and national decision-making is central to the political design of the Regulation. It allows the EU to reduce fragmentation without attempting to harmonise national healthcare budgets or reimbursement systems.

A broader European market-access environment

The long-term consequence may be the emergence of a more integrated European evidence environment. Developers will increasingly have to think about market access at European scale, while national authorities will work within a common scientific framework.

For patients, the test will ultimately be practical: whether the new architecture shortens the path from innovation to treatment. For companies, success will depend on adapting clinical and market-access strategies to a system in which evidence requirements are becoming more coordinated across the Union.

And for Member States, the challenge will be to translate the efficiency gained at European level into faster national decisions without losing the ability to respond to the needs and resources of their own healthcare systems.